title: Low prevalence of gingival overgrowth associated to new imunossupressive protocols with cyclosporin.
abstract: Gingival overgrowth (GO) is a frequent finding in patients treated with cyclosporine (CsA). This study investigated the prevalence and severity of GO in patients who received kidney transplant and CsA therapy, as well as associations with pharmacological and clinical factors. This cross-sectional study included 63 kidney transplant recipients who were treated with CsA in a university hospital. Demographic, pharmacological, and periodontal data were collected. The primary variable was GO. Independent sample t- and chi-square tests were used to compare means in groups with versus without GO. The response rate was 86.3%. Overall, 40% of patients had some degree of GO. Eleven individuals presented GO scores > 10%, and 5 individuals reached 30%. The mean GO percentage was low (6.79 ± 15.83). Patients that were concurrently under nifedipine treatment showed a non-significant trend toward a greater prevalence of GO. Mean CsA dosage and serum levels were 3.20 ± 0.94 mg/kg/d and 156.12 ± 162.75 ng/mL, respectively. There were no statistically significant differences between patients with versus without GO nor between the groups receiving nifedipine, no drug, or verapamil. The GO prevalence and severity rates were lower than those reported in previous studies and seemed to be independent of drug interactions.
authors.affiliation: School of Dentistry, Federal University of Santa Maria, Santa Maria, RS, Brazil.
authors.forename: Luiz Augusto
authors.initials: LA
authors.lastname: Wentz
authors.forename: Sara Cioccari
authors.initials: SC
authors.lastname: Oliveira
authors.forename: Carlos Heitor Cunha
authors.initials: CH
authors.lastname: Moreira
authors.forename: Cassiano Kuchenbecker
authors.initials: CK
authors.lastname: Rösing
mesh_terms: D000328:Adult; D000368:Aged; D001938:Brazil / Q000453:epidemiology; D016009:Chi-Square Distribution; D003430:Cross-Sectional Studies; D016572:Cyclosporine / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019214:Gingival Overgrowth / Q000139:chemically induced* / Q000453:epidemiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012720:Severity of Illness Index
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine